jerome zeldis  celgene corporation  zoominfocom metastat elevates jerome b zeldis md phd to chairman of the board and appoints douglas a hamilton metastat’s president and ceo to its board of directors  business wire metastat elevates jerome b zeldis md phd to chairman of the board and appoints douglas a hamilton metastat’s president and ceo to its board of directors renown drug developer becomes metastat’s chairman of the board may    am eastern daylight time bostonbusiness wiremetastat inc otcqbmtst a precommercial biotechnology company focused on the development and commercialization of companion diagnostics and antimetastatic therapeutics in the novel cancer treatments in drugs today announced the promotion of jerome b zeldis md phd from vice chairman to chairman and the appointment of douglas a hamilton metastat’s president and chief executive officer to its board of directors in connection with a restructuring of metastat’s board dr zeldis stated “metastat has an exciting technology platform based on the novel mechanisms that drive cancer metastasis and overcome tumor resistance to certain therapeutics creating the potential to discover novel cancer drugs i look forward to working with doug and the metastat team in solidifying our mission to discover and develop truly novel approaches for treating a variety of cancers” mr hamilton said “i am delighted jerry is leading metastat’s board of directors and honored to serve on the board with him we have a shared vision for the future of the company seeing multiple opportunities to make significant advances in treating cancer” mr hamilton continued “our driverbased diagnostic biomarkers are also therapeutic targets for the development of antimetastatic drugs and combination therapies to overcome drug resistance we plan to leverage our driverbased biomarkers and expand strategic partnerships to unlock opportunities in oncology” please see the company’s current report on form k filed with the securities and exchange commission on may   for full details on the board restructuring including the resignations of messrs berman goodeve and bronsther dr zeldis is the chief medical officer of sorrento therapeutics inc and previously served as chief medical officer of celgene corporation and chief executive officer of celgene global health until june  prior to joining celgene in  dr zeldis held positions at sandoz research institute and janssen research institute in both clinical research and medical affairs he currently serves as chairman of the board of alliqua and trek therapeutics in addition to board positions at ptc therapeutics and soligenix he was assistant professor of medicine at harvard medical school associate professor of medicine at university of california davis clinical associate professor of medicine at cornell medical school and professor of clinical medicine at the robert wood johnson medical school dr zeldis received ba and ms degrees from brown university and m phil md and phd degrees from yale university dr zeldis has published  peerreviewed articles and is a named inventor on  us patents mr hamilton has been president and ceo of metastat since june  previously mr hamilton served as cfo for sea medical systems and since  partner at new biology ventures a lifesciences incubator accelerator and consulting firm from  to  mr hamilton served as cfo and coo for javelin pharmaceuticals purchased by hospira where he led the company to commercialization and through its successful national markets uplisting prior to javelin mr hamilton was the cfo and director of business development for polarx biopharmaceuticals now teva pharmaceuticals mr hamilton held positions at amgen and pfizer in clinical research and product development sales and marketing at pharmacia biotechnology now ge healthcare life sciences and research at connaught laboratories now sanofipasteur mr hamilton earned his honors bachelor of science degree from the department of medical genetics at the university of toronto and his mba from the ivey business school at western university about metastat inc metastat is a precommercial biotechnology company focused on the discovery development and commercialization of diagnostics tests that are prognostic for risk of cancer metastasis companion diagnostics to predict drug response and therapeutics to prevent aggressive cancer from spreading metastat’s driverbased diagnostic and therapeutic discovery platform technology is based on the pivotal role of the mena protein and its isoforms a common pathway for the development of metastatic disease and drug resistance in all epithelialbased solid tumors metastat is based in boston ma forwardlooking statements this press release contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and such forwardlooking statements are made pursuant to the safe harbor provisions of the private securities litigation reform act of  you are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances events or results to differ materially from those projected in the forwardlooking statements as a result of various factors and other risks including those set forth in the companys form k and its other filings filed with the securities and exchange commission you should consider these factors in evaluating the forwardlooking statements included herein and not place undue reliance on such statements the forwardlooking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements contacts metastatrick pierce vprpiercemetastatcom hashtags diagnostics cancer breastcancer contacts metastatrick pierce vprpiercemetastatcom search advanced news search advanced news search log in sign up company news email alerts home company info overview leadership team board of directors partnerships and collaborations scientific and clinical advisors and collaborators technology overview the mena protein isoforms scientific  clinical publications  presentations patents and intellectual property videos pipeline therapeutics rx companion diagnostics cdx prognostic diagnostics pdx metasite breast™ menacalc™ platform media center recent news in the news industry news investors news  events company news in the news ir calendar email alerts company information profile presentations leadership team ir contacts faq financial information financials annual reports proxy conference calls stock information quote charts historical data sec filings all sec filings section  filings corporate governance board of directors governance documents contact us investors news  events company news in the news ir calendar email alerts company information financial information stock information sec filings corporate governance home  investors  news  events  company news company news email alerts tear sheet ir contacts rss news feed metastat elevates jerome b zeldis md phd to chairman of the board and appoints douglas a hamilton metastat’s president and ceo to its board of directors download pdf renown drug developer becomes metastat’s chairman of the board bostonbusiness wire metastat inc otcqbmtst a precommercial biotechnology company focused on the development and commercialization of companion diagnostics and antimetastatic therapeutics in the novel cancer treatments in drugs today announced the promotion of jerome b zeldis md phd from vice chairman to chairman and the appointment of douglas a hamilton metastat’s president and chief executive officer to its board of directors in connection with a restructuring of metastat’s board dr zeldis stated “metastat has an exciting technology platform based on the novel mechanisms that drive cancer metastasis and overcome tumor resistance to certain therapeutics creating the potential to discover novel cancer drugs i look forward to working with doug and the metastat team in solidifying our mission to discover and develop truly novel approaches for treating a variety of cancers” mr hamilton said “i am delighted jerry is leading metastat’s board of directors and honored to serve on the board with him we have a shared vision for the future of the company seeing multiple opportunities to make significant advances in treating cancer” mr hamilton continued “our driverbased diagnostic biomarkers are also therapeutic targets for the development of antimetastatic drugs and combination therapies to overcome drug resistance we plan to leverage our driverbased biomarkers and expand strategic partnerships to unlock opportunities in oncology” please see the company’s current report on form k filed with the securities and exchange commission on may   for full details on the board restructuring including the resignations of messrs berman goodeve and bronsther dr zeldis is the chief medical officer of sorrento therapeutics inc and previously served as chief medical officer of celgene corporation and chief executive officer of celgene global health until june  prior to joining celgene in  dr zeldis held positions at sandoz research institute and janssen research institute in both clinical research and medical affairs he currently serves as chairman of the board of alliqua and trek therapeutics in addition to board positions at ptc therapeutics and soligenix he was assistant professor of medicine at harvard medical school associate professor of medicine at university of california davis clinical associate professor of medicine at cornell medical school and professor of clinical medicine at the robert wood johnson medical school dr zeldis received ba and ms degrees from brown university and m phil md and phd degrees from yale university dr zeldis has published  peerreviewed articles and is a named inventor on  us patents mr hamilton has been president and ceo of metastat since june  previously mr hamilton served as cfo for sea medical systems and since  partner at new biology ventures a lifesciences incubator accelerator and consulting firm from  to  mr hamilton served as cfo and coo for javelin pharmaceuticals purchased by hospira where he led the company to commercialization and through its successful national markets uplisting prior to javelin mr hamilton was the cfo and director of business development for polarx biopharmaceuticals now teva pharmaceuticals mr hamilton held positions at amgen and pfizer in clinical research and product development sales and marketing at pharmacia biotechnology now ge healthcare life sciences and research at connaught laboratories now sanofipasteur mr hamilton earned his honors bachelor of science degree from the department of medical genetics at the university of toronto and his mba from the ivey business school at western university about metastat inc metastat is a precommercial biotechnology company focused on the discovery development and commercialization of diagnostics tests that are prognostic for risk of cancer metastasis companion diagnostics to predict drug response and therapeutics to prevent aggressive cancer from spreading metastat’s driverbased diagnostic and therapeutic discovery platform technology is based on the pivotal role of the mena protein and its isoforms a common pathway for the development of metastatic disease and drug resistance in all epithelialbased solid tumors metastat is based in boston ma forwardlooking statements this press release contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and such forwardlooking statements are made pursuant to the safe harbor provisions of the private securities litigation reform act of  you are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances events or results to differ materially from those projected in the forwardlooking statements as a result of various factors and other risks including those set forth in the companys form k and its other filings filed with the securities and exchange commission you should consider these factors in evaluating the forwardlooking statements included herein and not place undue reliance on such statements the forwardlooking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements view source version on businesswirecom httpwwwbusinesswirecomnewshomeen metastatrick pierce vprpiercemetastatcom source metastat inc released may   site info privacy policy disclaimer sitemap contact us careers investor quicklinks ir overview news  events investor presentation financial info ir contacts stock info ir faq sec filings connect with us email alerts rss metastat inc drydock ave nd floorboston ma   website by equisolve metastat elevates jerome b zeldis md phd to chairman of the board and appoints douglas a hamilton metastats president and ceo to its board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street metastat elevates jerome b zeldis md phd to chairman of the board and appoints douglas a hamilton metastats president and ceo to its board of directors business wire may    am edt metastat inc otcqbmtst a precommercial biotechnology company focused on the development and commercialization of companion diagnostics and antimetastatic therapeutics in the novel cancer treatments in drugs today announced the promotion of jerome b zeldis md phd from vice chairman to chairman and the appointment of douglas a hamilton metastats president and chief executive officer to its board of directors in connection with a restructuring of metastats board dr zeldis stated metastat has an exciting technology platform based on the novel mechanisms that drive cancer metastasis and overcome tumor resistance to certain therapeutics creating the potential to discover novel cancer drugs i look forward to working with doug and the metastat team in solidifying our mission to discover and develop truly novel approaches for treating a variety of cancers mr hamilton said i am delighted jerry is leading metastats board of directors and honored to serve on the board with him we have a shared vision for the future of the company seeing multiple opportunities to make significant advances in treating cancer mr hamilton continued our driverbased diagnostic biomarkers are also therapeutic targets for the development of antimetastatic drugs and combination therapies to overcome drug resistance we plan to leverage our driverbased biomarkers and expand strategic partnerships to unlock opportunities in oncology please see the companys current report on form k filed with the securities and exchange commission on may   for full details on the board restructuring including the resignations of messrs berman goodeve and bronsther dr zeldis is the chief medical officer of sorrento therapeutics inc and previously served as chief medical officer of celgene corporation and chief executive officer of celgene global health until june  prior to joining celgene in  dr zeldis held positions at sandoz research institute and janssen research institute in both clinical research and medical affairs he currently serves as chairman of the board of alliqua and trek therapeutics in addition to board positions at ptc therapeutics and soligenix he was assistant professor of medicine at harvard medical school associate professor of medicine at university of california davis clinical associate professor of medicine at cornell medical school and professor of clinical medicine at the robert wood johnson medical school dr zeldis received ba and ms degrees from brown university and m phil md and phd degrees from yale university dr zeldis has published  peerreviewed articles and is a named inventor on  us patents if you liked this article you might like microtest leaps on acquisition tsc staff jun    am edt trending ftc seen as set to block rite aid deal the  absolutely cheapest places to buy a house in america it would be crazy to clean house at wells fargo ceo says tesla ceo elon musk we are going to be in production hell for  months advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft jerome b zeldis addedit   you are here scientific experts  usa  celgene corporation  zeldis  jerome b zeldis research topicsthalidomideimmunologic factorsmultiple myelomadexamethasonelocal neoplasm recurrenceantineoplastic combined chemotherapy protocolssurvival rateneoplasmsdermatologic agentsimmunologic adjuvantsnon steroidal anti inflammatory agentsclinical trialsteratogensmaternal exposurepaternal exposurerisk managementantineoplastic agentsdrug induced abnormalitiesfetuspostmarketing product surveillancerisk assessmenterythropoiesismyelodysplastic syndromespulmonary embolismalgorithmsunited states food and drug administrationfactual databaseshalf lifestereoisomerismchronic kidney failurejerome b zeldissummaryaffiliation celgene corporationcountry usapublications lenalidomide in multiple myeloma current role and future directionsjerome b zeldiscelgene corporation  morris avenue summit nj  usaexpert opin pharmacother   a review of the history properties and use of the immunomodulatory compound lenalidomidejerome b zeldiscelgene corporation summit new jersey usaann n y acad sci   revassist a comprehensive risk minimization programme for preventing fetal exposure to lenalidomidecarmen p castanedaglobal drug safety celgene corporation summit new jersey  usadrug saf   thalidomide as a novel therapeutic agent new uses for an old productsteve k teocelgene corporation  powder horn drive warren nj  usadrug discov today   effectiveness of risk evaluation and mitigation strategies rems for lenalidomide and thalidomide patient comprehension and knowledge retentionnancy a brandenburgcelgene corporation  morris ave summit nj  usadrug saf   venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide results from postmarketing surveillance and data mining techniquesxionghu yangglobal drug safety celgene corporation summit new jersey usaclin drug investig   pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysisnianhang chencelgene corporation  morris avenue summit nj  usaj clin pharmacol  collaboratorssteven k teonianhang chengondi kumarmohamad husseinr a knightnancy a brandenburgrobert bwirejohn freemanxionghu yangcarmen p castanedapaul sheehanflorence hounmaria luisa salomoncurtis quigley detail informationpublications lenalidomide in multiple myeloma current role and future directionsjerome b zeldiscelgene corporation  morris avenue summit nj  usaexpert opin pharmacother  this review describes current data on lenalidomide in myeloma and how the unique properties of lenalidomide may lend its use in new settings such as maintenance and preventive therapy a review of the history properties and use of the immunomodulatory compound lenalidomidejerome b zeldiscelgene corporation summit new jersey usaann n y acad sci  several earlystage studies are exploring lenalidomide alone and in combination across different hematological malignancies solid tumors and immunerelated disorders revassist a comprehensive risk minimization programme for preventing fetal exposure to lenalidomidecarmen p castanedaglobal drug safety celgene corporation summit new jersey  usadrug saf  the pharmacy audit findings showed compliance with revassist was high although revassist is labourintensive timeconsuming and costly it continues to be effective in preventing fetal exposure to lenalidomide thalidomide as a novel therapeutic agent new uses for an old productsteve k teocelgene corporation  powder horn drive warren nj  usadrug discov today  the analogue lenalidomide has shown potential in treating the bone marrow disorders multiple myeloma and myelodysplastic syndrome and is presently in phase ii and iii trials respectively effectiveness of risk evaluation and mitigation strategies rems for lenalidomide and thalidomide patient comprehension and knowledge retentionnancy a brandenburgcelgene corporation  morris ave summit nj  usadrug saf  the effectiveness of patient education activities conducted within the lenalidomide and thalidomide risk evaluation and mitigation strategies rems programs was evaluated by measuring understanding of serious risk and safeuse messages venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide results from postmarketing surveillance and data mining techniquesxionghu yangglobal drug safety celgene corporation summit new jersey usaclin drug investig   pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysisnianhang chencelgene corporation  morris avenue summit nj  usaj clin pharmacol  a hour hemodialysis removed  of lenalidomide in the body therefore lenalidomide dose adjustments should be considered for patients with clcr   mlmin and the recommendations are given for the starting doses   labomeorg   all rights researvedprinceton new jersey  usalast updated february   ptc therapeutics appoints jerome b zeldis md phd to board of directors ptc therapeutics appoints jerome b zeldis md phd to board of directors sep    et from ptc therapeutics inc dr jerome zeldis prnewsfotoptc therapeutics inc     facebook twitter pinterest ptc therapeutics logo prnewsfotoptc therapeutics inc     facebook twitter pinterest dr jerome zeldis prnewsfotoptc therapeutics inc ptc therapeutics logo prnewsfotoptc therapeutics inc south plainfield nj sept   prnewswire  ptc therapeutics inc ptc today announced the appointment of jerome b zeldis md phd to the companys board of directors dr zeldis is the chief executive officer of celgene global health and the chief medical officer of celgene corporation in summit new jersey photo  httpphotosprnewswirecomprnhny logo  httpphotosprnewswirecomprnhptclogo we are honored to welcome dr zeldis to ptcs board of directors said stuart w peltz phd chief executive officer ptc therapeutics inc as an established leader in the development of therapies addressing high unmet medical need dr zeldis guidance will be extremely valuable as ptc advances ataluren through the clinical and regulatory approval process dr zeldis has been with celgene since  prior to his current role he served as senior vice president of clinical research and medical affairs prior to celgene dr zeldis worked at sandoz research institute and janssen research institute in both clinical research and medical development he is currently on the board of the semorex corporation the new jersey chapter of the arthritis foundation and the castlemans disease organization dr zeldis attended brown university for a ba ms followed by yale university for a mphil md and phd in molecular biophysics and biochemistry immunochemistry he trained in internal medicine at the ucla center for the health sciences and gastroenterology at the massachusetts general hospital and harvard medical school he was assistant professor of medicine at the harvard medical school associate professor of medicine at university of california davis clinical associate professor of medicine at cornell medical school and professor of clinical medicine at the robert wood johnson medical school in new brunswick new jersey dr zeldis has published  peer reviewed articles and  reviews book chapters and editorials ptc is an innovative company at an exciting juncture in the clinical development of ataluren an investigational new drug for nonsensemediated duchenne and beckers muscular dystrophy and cystic fibrosis said dr zeldis i look forward to being a part of the next phase of the companys growth and to working with ptc to support its broad pipeline in rare disorders cancer and other areas of high unmet medical need about ptc therapeutics incptc is a biopharmaceutical company focused on the discovery development and commercialization of orally administered smallmolecule drugs that target posttranscriptional control processes posttranscriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function ptcs internally discovered pipeline addresses multiple therapeutic areas including rare genetic disorders oncology and infectious diseases ptc has developed proprietary technologies that it applies in its drug discovery activities and that have served as the basis for collaborations with leading biopharmaceutical companies such as astrazeneca celgene genzyme merck pfizer and roche for more information visit the companys website at wwwptcbiocom source ptc therapeutics inc related links httpwwwptcbiocom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more oct    et preview ptc therapeutics receives  million grant award from the national institutes of health nih to support research for a treatment for dengue fever jul    et preview ptc therapeutics closes  million financing my news release contains wide tables view fullscreen read more jul    et ptc therapeutics to host conference call to discuss second jul    et ptc therapeutics announces promotion of dr joseph mcintosh to jul    et ptc therapeutics announces publication of data from act dmd in looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search metastat elevates jerome b zeldis md phd to chairman of the board and appoints douglas a hamilton metastat’s president and ceo to its board of directorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballmetastat elevates jerome b zeldis md phd to chairman of the board and appoints douglas a hamilton metastat’s president and ceo to its board of directorsbusiness wiremay  reblogsharetweetsharebostonbusiness wiremetastat inc mtst a precommercial biotechnology company focused on the development and commercialization of companion diagnostics and antimetastatic therapeutics in the novel cancer treatments in drugs today announced the promotion of jerome b zeldis md phd from vice chairman to chairman and the appointment of douglas a hamilton metastat’s president and chief executive officer to its board of directors in connection with a restructuring of metastat’s boarddr zeldis stated “metastat has an exciting technology platform based on the novel mechanisms that drive cancer metastasis and overcome tumor resistance to certain therapeutics creating the potential to discover novel cancer drugs i look forward to working with doug and the metastat team in solidifying our mission to discover and develop truly novel approaches for treating a variety of cancers”mr hamilton said “i am delighted jerry is leading metastat’s board of directors and honored to serve on the board with him we have a shared vision for the future of the company seeing multiple opportunities to make significant advances in treating cancer” mr hamilton continued “our driverbased diagnostic biomarkers are also therapeutic targets for the development of antimetastatic drugs and combination therapies to overcome drug resistance we plan to leverage our driverbased biomarkers and expand strategic partnerships to unlock opportunities in oncology”please see the company’s current report on form k filed with the securities and exchange commission on may   for full details on the board restructuring including the resignations of messrs berman goodeve and bronstherdr zeldis is the chief medical officer of sorrento therapeutics inc and previously served as chief medical officer of celgene corporation and chief executive officer of celgene global health until june  prior to joining celgene in  dr zeldis held positions at sandoz research institute and janssen research institute in both clinical research and medical affairs he currently serves as chairman of the board of alliqua and trek therapeutics in addition to board positions at ptc therapeutics and soligenix he was assistant professor of medicine at harvard medical school associate professor of medicine at university of california davis clinical associate professor of medicine at cornell medical school and professor of clinical medicine at the robert wood johnson medical school dr zeldis received ba and ms degrees from brown university and m phil md and phd degrees from yale university dr zeldis has published  peerreviewed articles and is a named inventor on  us patentsmr hamilton has been president and ceo of metastat since june  previously mr hamilton served as cfo for sea medical systems and since  partner at new biology ventures a lifesciences incubator accelerator and consulting firm from  to  mr hamilton served as cfo and coo for javelin pharmaceuticals purchased by hospira where he led the company to commercialization and through its successful national markets uplisting prior to javelin mr hamilton was the cfo and director of business development for polarx biopharmaceuticals now teva pharmaceuticals mr hamilton held positions at amgen and pfizer in clinical research and product development sales and marketing at pharmacia biotechnology now ge healthcare life sciences and research at connaught laboratories now sanofipasteur mr hamilton earned his honors bachelor of science degree from the department of medical genetics at the university of toronto and his mba from the ivey business school at western universityabout metastat incmetastat is a precommercial biotechnology company focused on the discovery development and commercialization of diagnostics tests that are prognostic for risk of cancer metastasis companion diagnostics to predict drug response and therapeutics to prevent aggressive cancer from spreading metastat’s driverbased diagnostic and therapeutic discovery platform technology is based on the pivotal role of the mena protein and its isoforms a common pathway for the development of metastatic disease and drug resistance in all epithelialbased solid tumors metastat is based in boston maread moreforwardlooking statementsthis press release contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and such forwardlooking statements are made pursuant to the safe harbor provisions of the private securities litigation reform act of  you are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances events or results to differ materially from those projected in the forwardlooking statements as a result of various factors and other risks including those set forth in the companys form k and its other filings filed with the securities and exchange commission you should consider these factors in evaluating the forwardlooking statements included herein and not place undue reliance on such statements the forwardlooking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statementsview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nextatt executives to run combined company after time warner dealreutersengineer finds pattern makes millions in stocksmoney morningsponsoredteslas musk hands over first model  electric cars to early buyersreutersmeg whitmans out will ge chief executive take over ubersiliconbeatwind projects in peril as indian states rethink purchasesbloombergdiscover it  out of  avg by k customersdiscover cardsponsoredloan move looms as bayern plan to keep sanchesomnisportanthony scaramuccis wife reportedly filed for divorce because he was hellbent on joining trumpbusiness insidermainstream model  holds promise  and peril  for teslaassociated pressthis will be in everyones household by banyan hillsponsoredthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderchevron and exxon mobil have a tough path ahead nyse traderyahoo finance videostocks mixed after heavy earnings weekcardiologist  foods you should quit immediatelygundry mdsponsoredthe real reason overseas manufacturing is coming to americayahoo financetrump to cops please dont be too nice while arresting thugs and dont worry about their heads when you toss them in the paddy wagonbusiness insiderchrissy teigen is ‘so happy’ donald trump blocked her on twitterking kong this girl is an ugly mut  id block her if i was on twitter too join the conversation   news on jerome b zeldis news home advertising board and executive moves energy health care hedge funds m  a private equity technology person jerome b zeldis ▼ topic all topics ▼ organizations find news about organizations alumni find news on alumni of any org industries find news on a particular market your contacts find news on your contacts sign up for free daily alerts on this feed by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions follow change feed jerome b zeldis jerome b zeldis is no longer serving in their board position at kalytera therapeutics inc may    •  relsci data update kalytera announces changes to its board of directors may    •  globenewswire  its board of directors kalytera also announced the resignations of jerome b zeldis md phd director and david stefansky chairman we are grateful to dr  metastat elevates jerome b zeldis md phd to chairman of the board and appoints douglas a hamilton metastats president and ceo to its board of directors may    •  business wire  novel cancer treatments in drugs today announced the promotion of jerome b zeldis md phd from vice chairman to chairman and the appointment of douglas  sorrento and wildcat announce resolution march    •  pr newswire   audit firm deloitte and enhanced its senior executive team dr jerome zeldis md phd former chief medical officer at celgene corporation has been appointed  sorrentos tnk therapeutics provides progress update for its anticd and cd cart programs for treatment of hematological malignancies december    •  pr newswire  and we are excited to further its development in the clinic said dr�jerome zeldis�chief medical officer of sorrento therapeutics and president�of tnk therapeutics dr�zeldis�added we  a drug company on a mission of affordability november    •  the washington post  jerome zeldis remembers how he felt when he heard about the  price  bionor h  interim financial report august    •  thomson reuters one  on  june  board members benedicte fossum kirsten drejer and jerome b zeldis resigned from the board on  april   on   bionor q  interim financial report may    •  thomson reuters one  acting ceo  three board members benedicte fossum kirsten drejer and jerome b zeldis resigned from the board on  april  financial guidance for  metastat appoints jerome b zeldis md phd to its board of directors april    •  business wire  otcqbmtst a molecular diagnostic company today announced the appointment of jerome b zeldis md phd to serve as vice chairman of the companys board of  biosig technologies inc issues special letter to shareholders december    •  marketwired  a banner year in strengthening our already leading board of directors dr jerome zeldis current chief medical officer of celgene inc nasdaqcelg joined in april  kalytera therapeutics appoints dr jerome zeldis to board of directors december    •  marketwired  has appointed jerome b zeldis md phd to its board of directors dr zeldis serves as the chief medical officer of celgene corporation nasdaq celg  ovid therapeutics appoints dr jerome b zeldis to its scientific advisory board october    •  business wire  officer of celgene global health and chief medical officer of celgene corporation dr zeldis is noted for his exceptional and successful experience in drug development  biosig technologies announces the appointment of jerome b zeldis to its board of directors april    •  marketwired  biosig technologies otcqb bsgm today announced that dr jerome b zeldis has joined the companys board of directors effective immediately dr  idenix ceo elected to board of ptc therapeutics a day after news of merck sale june    •  boston business journal  also reelected to the board tuesday was ptcs ceo stuart peltz and jerome zeldis ceo of celgene global health ptc is one of three biotechs  bio reveals program for  bio convention in china october    •  business wire  china country president shire kochung lin phd founder  ceo pharmaessentia jerry zeldis phd chief executive officer celgene global health and chief medical officer celgene  healthcare companies in the news for july   alliqua inc derma sciences mimedx integra lifesciences oculus innovativecm derma sciences inc july    •  pr newswire  by group of alliqua  s management and board of directors including jerome zeldis dave johnson david stefansky joseph leone and kenneth pearsen dr zeldis  alliqua raises  million in nd quarter of  led by members of management and its board of directors july    •  pr newswire  by group of alliqua  s management and board of directors including jerome zeldis dave johnson david stefansky joseph leone and kenneth pearsen dr zeldis  letter from alliqua ceo dave johnston to shareholders march    •  pr newswire  on our already experienced board of directors through the appointment of dr jerry zeldis as chairman jerry continues to serve as the chief medical officer  letter from alliqua ceo dave johnston to shareholders march    •  pr newswire  on our already experienced board of directors through the appointment of dr jerry zeldis as chairman jerry continues to serve as the chief medical officer  related news feeds trek therapeutics alumni of brown university jerome b zeldis email linkedin facebook google tweet reddit permalink want to see the full history of news or view news on a particular date upgrade to relsci professional now start my free trial ➤ industry select a topic keyword go  ➤ find an organization select a topic keyword go  ➤ find a person select a topic keyword go  ➤ name of a school or name of an organization select a topic keyword go  ➤ thank you you are now subscribedplease wait for the page to refresh you are now subscribed to this feed you have unsubscribed to this feed thank you you can now subscribe to more relsci news feeds to subscribe to more than one feed please enter a password please confirm your password go  ➤ youve found a premium relsci pro feature follow news on your contacts upgrade to relsci pro now to easily sync your contacts and stay in the know on the news about the people important to you start my free trial ➤ still not convinced check out our full listing of features here not now youve found a premium relsci pro feature search news on keywords curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles start my free trial ➤ still not convinced check out our full listing of features here not now industries find news on a particular market people find news about people organizations find news about organizations alumni find news on alumni of any org your contacts find news on your contacts free daily alerts sign up for free daily alerts on this feed sign up ➤ by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions already have an account click here to login are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤